{"brief_title": "Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis", "brief_summary": "OBJECTIVES: I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. All patients self-administer daily subcutaneous injections of human parathyroid hormone (1-34) or placebo for a period of 2.5 years. Patients are followed regularly for unacceptable toxicities. Completion date provided represents the completion date of the grant per OOPD records", "condition": "Osteoporosis", "intervention_type": "Drug", "intervention_name": "human parathyroid hormone", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Osteoporosis as defined by: Bone mineral density at the lumbar spine or femoral neck that is 2.5 standard deviations below peak bone mass reference value (T score less than -2.5) No family history of male osteoporosis No other metabolic bone disease --Prior/Concurrent Therapy-- Endocrine therapy: - No concurrent glucocorticoid therapy - No prior steroid use Surgery: No prior gastrointestinal tract surgery Other: No prior or concurrent anticonvulsant therapy --Patient Characteristics-- Hematopoietic: Normal CBC Hepatic: Normal liver function Renal: Normal renal function Other: - Normal thyroid function - Normal adrenal function - Normal gonadal status - No myeloma or other malignancy - No alcoholism, hypercortisolism or diabetes mellitus - No gastrointestinal tract disease or disorder associated with malabsorption", "gender": "Male", "minimum_age": "29 Years", "maximum_age": "67 Years", "healthy_volunteers": "No", "id": "NCT00004406.xml"}